A novel adjuvant, the mixture of alum and naltrexone, augments vaccine-induced immunity against Plasmodium berghei

References

• Aguilar JC, Rodriguez EG. (2007). Vaccine adjuvants revisited. Vaccine, 25, 3752–62
   PubMed Web of Science ®Google Scholar
• Aimanianda V, Haensler J, Lacroix-Desmazes S, et al. (2009). Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci, 30, 287–95
   PubMed Web of Science ®Google Scholar
• Bansal A, Paliwal PK, Sagi SS, Sairam M. (2010). Effect of adjuvants on immune response and protective immunity elicited by recombinant Hsp60 (GroEL) of Salmonella typhi against S. typhi infection. Mol Cell Biochem, 337, 213–21
   PubMedGoogle Scholar
• Bayry J, Tchilian EZ, Davies MN, et al. (2008). In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci USA, 105, 10221–6
   PubMed Web of Science ®Google Scholar
• Bayry J, Triebel F, Kaveri SV, Tough DF. (2007). Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol, 178, 4184–93
   PubMed Web of Science ®Google Scholar
• Bell J, Kimber J, Lintzeris N, et al. (2003). Clinical guidelines and procedures for the use of naltrexone in the management of opioid dependence. Canberra: Australian Government Department of Health and Ageing
   Google Scholar
• Berman AS, Chancellor-Freeland C, Zhu G, Black PH. (1996). Substance P primes murine peritoneal macrophages for an augmented proinflammatory cytokine response to lipopolysaccharide. Neuroimmunomodulation, 3, 141–9
   PubMed Web of Science ®Google Scholar
• Bileviciute-Ljungar I, Spetea M. (2001). Contralateral but not systemic administration of the kappa-opioid agonist U-50,488H induces anti-nociception in acute hindpaw inflammation in rats. Br J Pharmacol, 132, 252–8
   PubMedGoogle Scholar
• Casadevall A. (2003). Antibody-mediated immunity against intracellular pathogens: Two-dimensional thinking comes full circle. Infect Immun, 71, 4225–8
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. (2006). A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol, 91, 1–44
   PubMed Web of Science ®Google Scholar
• Coler RN, Carter D, Friede M, Reed SG. (2009). Adjuvants for malaria vaccines. Parasite Immunol, 31, 520–8
   PubMed Web of Science ®Google Scholar
• D’Argenio DA, Wilson CB. (2010). A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design. Immunity, 33, 437–40
   PubMedGoogle Scholar
• Davies MN, Bayry J, Tchilian EZ, et al. (2009). Toward the discovery of vaccine adjuvants: Coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS One, 4, e8084
   PubMed Web of Science ®Google Scholar
• De Gregorio E, Tritto E, Rappuoli R. (2008). Alum adjuvanticity: Unraveling a century old mystery. Eur J Immunol, 38, 2068–71
   PubMed Web of Science ®Google Scholar
• Douradinha B, Doolan DL. (2011). Harnessing immune responses against Plasmodium for rational vaccine design. Trends Parasitol, 27, 274–83
   Google Scholar
• Drugs.com [Internet]. Vivitrol Approval History. c 2000-2014. [Updated: 2014 May 5; Cited: 2014 June 6]. Available from: http://www.drugs.com/history/vivitrol.html
   Google Scholar
• Good MF, Doolan DL. (2010). Malaria vaccine design: Immunological considerations. Immunity, 33, 555–66
   PubMed Web of Science ®Google Scholar
• Guo CJ, Douglas SD, Gao Z, et al. (2004). Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. Glia, 48, 259–66
   PubMed Web of Science ®Google Scholar
• Gupta RK, Siber GR. (1995). Adjuvants for human vaccine—current status, problems and future prospects. Vaccine, 13, 1263–76
   PubMed Web of Science ®Google Scholar
• Harandi AM, Medaglini D, Shattock RJ. (2010). Vaccine adjuvants: A priority for vaccine research. Vaccine, 28, 2363–6
   PubMed Web of Science ®Google Scholar
• Hem SL, White JL. (1995). Structure and properties of aluminum-containing adjuvants. Pharm Biotechnol, 6, 249–76
   PubMedGoogle Scholar
• Houot R, Perrot I, Garcia E, et al. (2006). Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol, 176, 5293–8
   PubMed Web of Science ®Google Scholar
• Jacobs P, Radzioch D, Stevenson MM. (1996). A Th1-associated increase in tumor necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice. Infect Immun, 64, 535–41
   PubMedGoogle Scholar
• Jamali A, Mahdavi M, Hassan ZM, et al. (2009). A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int Immunol, 21, 217–25
   PubMedGoogle Scholar
• Jamali A, Mahdavi M, Shahabi S, et al. (2007). Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. Microb Pathog, 43, 217–23
   PubMed Web of Science ®Google Scholar
• Jazani NH, Karimzad M, Mazloomi E, et al. (2010). Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed Listeria monocytogenes vaccine. Microbes Infect, 12, 382–8
   PubMed Web of Science ®Google Scholar
• Jazani NH, Parsania S, Sohrabpour M, et al. (2011a). Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella typhimurium infection. Immunobiology, 216, 744–51
   PubMedGoogle Scholar
• Jazani NH, Sohrabpour M, Mazloomi E, Shahabi S. (2011b). A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. FEMS Immunol Med Microbiol, 61, 54–62
   PubMedGoogle Scholar
• Lindblad EB. (2004). Aluminium compounds for use in vaccines. Immunol Cell Biol, 82, 497–505
   PubMed Web of Science ®Google Scholar
• Marriott I, Bost KL. (2000). IL-4 and IFN-gamma up-regulate substance P receptor expression in murine peritoneal macrophages. J Immunol, 165, 182–91
   PubMed Web of Science ®Google Scholar
• Mathers AR, Tckacheva OA, Janelsins BM, et al. (2007). In vivo signaling through the neurokinin 1 receptor favors transgene expression by Langerhans cells and promotes the generation of Th1- and Tc1-biased immune responses. J Immunol, 178, 7006–17
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Yukitake H, Kanbara H, et al. (2000). Mycobacterium bovis bacillus calmette-guerin induces protective immunity against infection by Plasmodium yoelii at blood-stage depending on shifting immunity toward Th1 type and inducing protective IgG2a after the parasite infection. Vaccine, 19, 779–87
   PubMedGoogle Scholar
• McKee AS, Munks MW, MacLeod MK, et al. (2009). Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol, 183, 4403–14
   PubMed Web of Science ®Google Scholar
• Molla Hassan AT, Hassan ZM, Moazzeni SM, et al. (2009). Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice. Int Immunopharmacol, 9, 1381–6
   PubMedGoogle Scholar
• Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Meth, 65, 55–63
   PubMed Web of Science ®Google Scholar
• Perrie Y, Mohammed AR, Kirby DJ, et al. (2008). Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens. Int J Pharm, 364, 272–80
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. (2004). Vaccine adjuvants: Current state and future trends. Immunol Cell Biol, 82, 488–96
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. (2009). New horizons in adjuvants for vaccine development. Trends Immunol, 30, 23–32
   PubMed Web of Science ®Google Scholar
• Stevenson MM, Tam MF. (1993). Differential induction of helper T cell subsets during blood-stage Plasmodium chabaudi AS infection in resistant and susceptible mice. Clin Exp Immunol, 92, 77–83
   PubMed Web of Science ®Google Scholar
• Su Z, Tam MF, Jankovic D, Stevenson MM. (2003). Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice. Infect Immun, 71, 5178–87
   PubMed Web of Science ®Google Scholar
• Tagliabue A, Rappuoli R. (2008). Vaccine adjuvants: The dream becomes real. Hum Vaccin, 4, 347–9
   PubMed Web of Science ®Google Scholar
• Tang Q, Adams JY, Tooley AJ, et al. (2006). Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol, 7, 83–92
   PubMed Web of Science ®Google Scholar
• Tappeh KH, Khorshidvand Z, Shahabi S, Mohammadzadeh H. (2013). A novel adjuvant, mixture of alum and naltrexone, elicits humoral immune responses for excreted/secreted antigens of toxoplasma gondii tachyzoites vaccine in Balb/c murine model. Turkiye Parazitol Derg, 37, 92–6
   PubMedGoogle Scholar
• Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. (2001). The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun, 69, 1151–9
   PubMed Web of Science ®Google Scholar